Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Nov 15;61 Suppl 5(Suppl 5):S521-30.
doi: 10.1093/cid/civ518.

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years

Aldiouma Diallo  1 , Samba O Sow  2 , Olubukola T Idoko  3 , Siddhivinayak Hirve  4 , Helen Findlow  5 , Marie-Pierre Preziosi  6 , Cheryl Elie  7 , Prasad S Kulkarni  8 , Varsha Parulekar  9 , Bou Diarra  1 , Fadima Cheick Haidara  2 , Fatoumata Diallo  2 , Milagritos Tapia  10 , Adebayo K Akinsola  3 , Richard A Adegbola  11 , Ashish Bavdekar  4 , Sanjay Juvekar  4 , Julie Chaumont  12 , Lionel Martellet  12 , Elisa Marchetti  12 , Marc F LaForce  8 , Brian D Plikaytis  7 , Godwin C Enwere  12 , Yuxiao Tang  13 , Ray Borrow  5 , George Carlone  7 , Simonetta Viviani  12
Affiliations
Randomized Controlled Trial

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years

Aldiouma Diallo et al. Clin Infect Dis. .

Abstract

Background: Mass vaccination campaigns of the population aged 1-29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in India and found to be safe and highly immunogenic compared with the group A component of the licensed quadrivalent polysaccharide vaccine (PsACWY). Antibody persistence in Africa and in India was investigated.

Methods: A total of 900 subjects aged 2-29 years were followed up for 4 years in Senegal, Mali, and The Gambia (study A). A total of 340 subjects aged 2-10 years were followed up for 1 year in India (study B). In study A, subjects were randomized in a 2:1 ratio, and in study B a 1:1 ratio to receive either PsA-TT or PsACWY. Immunogenicity was evaluated by measuring MenA serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific immunoglobulin G (IgG) enzyme-linked immunosorbent assay.

Results: In both studies, substantial SBA decay was observed at 6 months postvaccination in both vaccine groups, although more marked in the PsACWY group. At 1 year and 4 years (only for study A) postvaccination, SBA titers were relatively sustained in the PsA-TT group, whereas a slight increasing trend, more pronounced among the youngest, was observed in the participants aged <18 years in the PsACWY groups. The SBA titers were significantly higher in the PsA-TT group than in the PsACWY group at any time point, and the majority of subjects in the PsA-TT group had SBA titers ≥128 and group A-specific IgG concentrations ≥2 µg/mL at any point in time in both the African and Indian study populations.

Conclusions: Four years after vaccination with a single dose of PsA-TT vaccine in Africa, most subjects are considered protected from MenA disease.

Clinical trials registration: PsA-TT-003 (ISRCTN87739946); PsA-TT-003a (ISRCTN46335400).

Keywords: African meningitis belt; India; MenA conjugate vaccine; antibody persistence.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Disposition of subjects in study A conducted in healthy 2- to 29-year-olds.
Figure 2.
Figure 2.
Serum bactericidal antibody (SBA) geometric mean titers (GMTs) over time for study A and study B.
Figure 3.
Figure 3.
Group A–specific immunoglobulin G (IgG) geometric mean concentrations (GMCs) over time for study A and study B.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lapeyssonie L. La méningite cérébrospinale en Afrique. Bull World Health Organ 1963; 28(suppl):3–114. - PMC - PubMed
    1. Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa—has anything changed? Trop Med Int Health 2006; 11:773–80. - PubMed
    1. LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009; 27(suppl 2):B13–9. - PubMed
    1. Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003; 361:1902–4. - PubMed
    1. LaForce FM, Konde K, Viviani S, Preziosi MP. The Meningitis Vaccine Project. Vaccine 2007; 25(suppl 1):A97–100. - PubMed

Publication types

MeSH terms

Associated data